Skip Navigation

Cardiovascular Research 2005 67(3):419-425; doi:10.1016/j.cardiores.2005.04.022
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Roden, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roden, D. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Proarrhythmia as a pharmacogenomic entity: A critical review and formulation of a unifying hypothesis

Dan M. Roden*

Departments of Medicine and Pharmacology, Director, Oates Institute for Experimental Therapeutics, Vanderbilt University School of Medicine, 532 Medical Research Building I, Nashville, TN 37232, United States

* Tel.: +1 615 322 0067; fax: +1 615 343 4522. Email address: dan.roden{at}vanderbilt.edu

Proarrhythmia represents an extreme example of the phenomenon that drug effects vary widely among individuals. Studies of mechanisms leading to proarrhythmia have had important implications for understanding arrhythmogenesis, rational use of antiarrhythmic therapies, selection of patients for specific therapies, and drug development. In addition, because proarrhythmia often seems to develop in the absence of clear risk predictors, a role for genetics in predisposing to this adverse drug reaction has been postulated. This review presents mechanisms whereby genetic factors may contribute to variable drug responses and describes our current understanding of how these mechanisms play a role in proarrhythmia. A unifying hypothesis is presented: physiologic processes (such as drug elimination or cardiac repolarization) include multiple redundancies, and congenital or acquired absence of such redundancies – due to disease, interacting drugs, or genetic makeup – may confer no baseline phenotype, but nevertheless enhance susceptibility to unusual drug responses.

KEYWORDS Drugs; Proarrhythmia; Pharmacogenetics; Ion channels

Time for primary review 30 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. ProteomicsHome page
C.-L. Han, C.-W. Chien, W.-C. Chen, Y.-R. Chen, C.-P. Wu, H. Li, and Y.-J. Chen
A Multiplexed Quantitative Strategy for Membrane Proteomics: Opportunities for Mining Therapeutic Targets for Autosomal Dominant Polycystic Kidney Disease
Mol. Cell. Proteomics, October 1, 2008; 7(10): 1983 - 1997.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
D. M. Roden, R. B. Altman, N. L. Benowitz, D. A. Flockhart, K. M. Giacomini, J. A. Johnson, R. M. Krauss, H. L. McLeod, M. J. Ratain, M. V. Relling, et al.
Pharmacogenomics: Challenges and Opportunities.
Ann Intern Med, November 21, 2006; 145(10): 749 - 757.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
C. R. Bezzina, A. A.M. Wilde, and D. M. Roden
The molecular genetics of arrhythmias
Cardiovasc Res, August 15, 2005; 67(3): 343 - 346.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.